Trial · NCT03926052
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Binge-Eating Relapse | LDX (Lisdexamfetamine Dimesylate) | 3 | Participants | ||
| Binge-Eating Relapse | Placebo | 5 | Participants | ||
| Binge-Eating Relapse | LDX (Lisdexamfetamine Dimesylate) | 6 | Participants | ||
| Binge-Eating Relapse | Placebo | 6 | Participants | ||
| Binge-Eating Relapse | LDX (Lisdexamfetamine Dimesylate) | 3 | Participants | ||
| Binge-Eating Relapse | Placebo | 2 | Participants | ||
| Change in Binge-Eating Frequency | LDX (Lisdexamfetamine Dimesylate) | 1.33 | Standard Deviation 5.82 | episodes per the past 28 days | |
| Change in Binge-Eating Frequency | Placebo | 1.61 | Standard Deviation 4.37 | episodes per the past 28 days | |
| Change in Binge-Eating Frequency | LDX (Lisdexamfetamine Dimesylate) | 2.45 | Standard Deviation 5.39 | episodes per the past 28 days | |
| Change in Binge-Eating Frequency | Placebo | 1.00 | Standard Deviation 6.86 | episodes per the past 28 days | |
| Change in Binge-Eating Frequency | LDX (Lisdexamfetamine Dimesylate) | 1.28 | Standard Deviation 4.14 | episodes per the past 28 days | |
| Change in Binge-Eating Frequency | Placebo | -.09 | Standard Deviation 2.29 | episodes per the past 28 days | |
| Change in Eating-Disorder Psychopathology (Continuous) | LDX (Lisdexamfetamine Dimesylate) | -0.05 | Standard Deviation 0.77 | score on a scale | |
| Change in Eating-Disorder Psychopathology (Continuous) | Placebo | 0.50 | Standard Deviation 0.64 | score on a scale | |
| Change in Eating-Disorder Psychopathology (Continuous) | LDX (Lisdexamfetamine Dimesylate) | 0.23 | Standard Deviation 0.95 | score on a scale | |
| Change in Eating-Disorder Psychopathology (Continuous) | Placebo | 0.17 | Standard Deviation 0.60 | score on a scale | |
| Change in Eating-Disorder Psychopathology (Continuous) | LDX (Lisdexamfetamine Dimesylate) | 0.09 | Standard Deviation 0.83 | score on a scale | |
| Change in Eating-Disorder Psychopathology (Continuous) | Placebo | -0.07 | Standard Deviation 0.59 | score on a scale | |
| Change in Depressive Symptoms | LDX (Lisdexamfetamine Dimesylate) | 2.16 | Standard Deviation 5.27 | score on a scale | |
| Change in Depressive Symptoms | Placebo | 0.18 | Standard Deviation 7.07 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03926052/results